Genor Biopharma Holdings Past Earnings Performance
Past criteria checks 0/6
Genor Biopharma Holdings has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been declining at an average rate of 5.7% per year.
Key information
10.2%
Earnings growth rate
22.4%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | -5.7% |
| Return on equity | -56.7% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully
Dec 29
We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely
Dec 21Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?
Sep 05We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth
Dec 03Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation
Aug 28Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?
May 10Revenue & Expenses BreakdownBeta
How Genor Biopharma Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -674 | 125 | 485 |
| 30 Sep 23 | 6 | -637 | 134 | 495 |
| 30 Jun 23 | 13 | -599 | 143 | 504 |
| 31 Mar 23 | 14 | -665 | 180 | 544 |
| 31 Dec 22 | 16 | -730 | 217 | 584 |
| 30 Sep 22 | 9 | -800 | 263 | 610 |
| 30 Jun 22 | 3 | -870 | 309 | 636 |
| 31 Mar 22 | 1 | -868 | 307 | 625 |
| 31 Dec 21 | 0 | -865 | 306 | 613 |
| 30 Sep 21 | 3 | -1,880 | 299 | 617 |
| 30 Jun 21 | 7 | -2,895 | 292 | 620 |
| 31 Mar 21 | 10 | -3,086 | 281 | 721 |
| 31 Dec 20 | 10 | -3,027 | 241 | 697 |
| 31 Mar 20 | 12 | -590 | 116 | 480 |
| 31 Dec 19 | 13 | -522 | 89 | 439 |
| 31 Dec 18 | 7 | -288 | 22 | 271 |
Quality Earnings: 6998 is currently unprofitable.
Growing Profit Margin: 6998 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6998 is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare 6998's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6998 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 6998 has a negative Return on Equity (-56.71%), as it is currently unprofitable.